AntriaBio

Overview

Product Pipeline

Overview

Compound Discovery Preclinical Phase I Phase II

AB101

Injectable once-weekly basal insulin for type 1 and type 2 diabetes
Discovery Phase completed
Pre-Clinical Phase in progress

AB301

Injectable once-weekly GLP-1 agonist/basal insulin combination for type 2 diabetes
Discovery Phase completed
Pre-Clinical Phase in progress

In addition to the above, AntriaBio's extended release platform can be used to develop a range of differentiated long-acting injectable therapies.